AdAlta Hires FujiFilm to Produce Potential Therapeutic for IPF Patients
AdAlta, a biotech that develops protein-based therapeutics, has retained FujiFilm Diosynth Biotechnologies to manufacture AD-114, AdAlta’s lead drug molecule for the treatment of idiopathic pulmonary fibrosis (IPF). AdAlta is using its proprietary technology platform to create i-bodies, a new class of protein therapeutics that are the human equivalent of the antigen-binding domain…